Drugs Details

Drugs Info of Kinevac
Drugs Details
  • Drugs Type  : Multum
  • Date : 10th Feb 2015 07:07 am
  • Brand Name : Kinevac
  • Generic Name : sincalide (Pronunciation: SIN ka lide)
Descriptions

Kinevac (Sincalide for Injection) is a cholecystopancreatic-gastrointestinal hormone peptide for parenteral administration. The agent is a synthetically-prepared C-terminal octapeptide of cholecystokinin. Each via] of sincalide provides a sterile nonpyrogenic lyophilized white powder consisting of 5 mcg sincalide with 45 mg sodium chloride to provide tonicity; sodium hydroxide or hydrochloric acid may have been added prior to lyophilization for pH adjustment (5.5 to 6.5). At the time of manufacture, the air in the vial is replaced with nitrogen. Sincalide is designated chemically as L-aspartyl-L-tyrosyl-L-methionylglycyl-L-tryptophyl-L-methionyl-L-aspartylphenyK-alaninamide hydrogen sulfate (ester). Graphic formula:

 

KINEVAC® (Sincalide) Structural Formula Illustration

What are the possible side effects of sincalide (Kinevac)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Less serious side effects are more likely, such as:

  • stomach pain or discomfort;
  • nausea, vomiting, diarrhea;
  • headache;
  • feeling light-headed or short of breath;
  • sweating, flushing (warmth, redness, or tingly feeling);
  • sneezing; or
  • mild skin rash.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about...

Read All Potential Side Effects and See Pictures of Kinevac »

This monograph has been modified to include the generic and brand name in many instances.

Indications

Kinevac (Sincalide for Injection) may be used: (1) to stimulate gallbladder contraction, as may be assessed by contrast agent cholecystography or ultrasonography, or to obtain by duodenal aspiration a sample of concentrated bile for analysis of cholesterol, bile salts, phospholipids, and crystals; (2) to stimulate pancreatic secretion (especially in conjunction with secretin) prior to obtaining a duodenal aspirate for analysis of enzyme activity, composition, and cytology; (3) to accelerate the transit of a barium meal through the small bowel, thereby decreasing the time and-extent of radiation associated with fluoroscopy and x-ray examination of the intestinal tract.

Dosage Administration

Reconstitution and Storage

Sincalide for injection may be stored at room temperature prior to reconstitution.

To reconstitute, aseptically add 5 mL of Sterile Water for Injection USP to the vial; any additional dilution should be made with Sodium Chloride Injection USP, 0.9%. The solution may be kept at room temperature and should be used within 24 hours of reconstitution, after which time any unused portion should be discarded.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

For prompt contraction of the gallbladder, a dose of 0.02 mcg sincallde per kg (1.4 mcg/70 kg) is Injected intravenously over a 30- to 60-second interval; If satisfactory contraction of the gallbladder does not occur in 15 minutes, a second dose, 0.04 mcg sincalide per kg, may be administered. To reduce the intestinal side effects (see ADVERSE REACTIONS), an intravenous infusion may be prepared at a dose of 0.12 mcg/kg in 100 mL of Sodium Chloride Injection USP and given at a rate of 2 mL per minute; alternatively, an intramuscular dose of 0.1 mcg/kg may be given. When Kinevac (Sincalide for Injection) is used in cholecystography, roentgenograms are usually taken at five-minute Intervals after the injection. For visualization of the cystic duct, it may be necessary to take roentgenograms at one-minute intervals during the first five minutes after the injection.

For the Secretin-Kinevac (sincalide) test of pancreatic function, the patient receives a dose of 0.25 units secretin per kg by intravenous infusion over a 60-mlnute period. Thirty minutes after the initiation of the secretin infusion, a separate IV infusion of Kinevac (sincalide) at a total dose of 0.02 mcg per kg is administered over a 30-minute interval. For example, the total dose for a 70 kg patient is 1.4 mcg of sincalide; therefore, dilute 1.4 mL of reconstituted Kinevac (sincalide) solution to 30 mL with Sodium Chloride Injection USP and administer at a rate of 1 mL per minute.

To accelerate the transit time of a barium meal through the small bowel, administer Kinevac (sincalide) after the barium meal is beyond the proximal jejunum. (Sincalide, like cholecystokinin, may cause pyloric contraction.) The recommended dose is 0.04 mcg sincalide per kg (2.8 mcg/70 kg) injected intravenously over a 30- to 60-second interval; if satisfactory transit of the barium meal has not occurred in 30 minutes, a second dose of 0.04 mcg sincalide per kg may be administered. For reduction of side effects, a 30-minute IV infusion of sincalide [0.12 mcg per kg (8.4 mcg/70 kg) diluted to approximately 100 mL with Sodium Chloride Injection USP] may be administered.

How Supplied

Kinevac (Sincalide for Injection) is supplied in packages of 10 vials containing 5 mcg of sincalide per via] (NDC 0270-0556-15).

Storage

Store at room temperature, 15°-30° C (59°-86° F).

Manufactured for: Bracco Diagnostics Inc. Princeton, N.J. 08543. By E.R. Squibb & Sons Inc. New Brunswick, N.J. 08903. Revised November-1994. FDA Rev date: 4/26/2005

This monograph has been modified to include the generic and brand name in many instances.

Side Effects

Reactions to sincalide are generally mild and of short duration. The most frequent adverse reactions were abdominal discomfort or pain, and nausea; rapid intravenous injection of 0.04 mcg sincalide per kg expectably causes transient abdominal cramping. These phenomena are usually manifestations of the physiologic action of the drug, including delayed gastric emptying and increased intestinal motility. These reactions occurred in approximately 20 percent of patients; they are not to be construed as necessarily indicating an abnormality of the biliary tract unless there is other clinical or radiologic evidence of disease.

The incidence of other adverse reactions, including vomiting, flushing, sweating, rash, hypotension, hypertension, shortness of breath, urge to defecate, headache, diarrhea, sneezing, and numbness was less than 1 percent; dizziness was reported in approximately 2 percent of patients. These manifestations are usually lessened by slower injection rate.

Read the Kinevac (sincalide) Side Effects Center for a complete guide to possible side effects

Learn More »

Interactions

No information provided.

This monograph has been modified to include the generic and brand name in many instances.

Warnings

Because of Kinevac (sincalide) 's effect on smooth muscle, pregnant patients should be advised that spontaneous abortion or premature induction of labor may occur (see Pregnancy Category B).

Precautions

General

The possibility exists that stimulation of gallbladder contraction in patients with small gallbladder stones could lead to the evacuation of the stones from the gallbladder, resulting in their lodging in the cystic duct or in the common bile duct. The risk of such an event is considered to be minimal because sincalide, when given as directed, does not ordinarily cause complete contraction of the gallbladder.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term studies in animals have not been performed to evaluate carcinogenic or mutagenic potential, or possible impairment of fertility in males or females.

Teratogenic Effects

Pregnancy Category B

Reproduction studies in rats in which sincalide was administered subcutaneously at doses up to 12.5 times the maximum recommended human dose revealed no evidence of harm to the fetus due to sincalide. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed (see WARNINGS).

Labor and Delivery

Sincalide should not be administered to pregnant women near term because of its effect on smooth muscle; the possibility of inducing labor prematurely exists. The effects of sincalide on labor, delivery and lactation in animals has not been determined (see WARNINGS).

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when sincalide is administered to a nursing woman.

Pediatric Use

Safety and effectiveness in children have not been established.

This monograph has been modified to include the generic and brand name in many instances.

OverDose

Although no overdosage reports have been received, gastrointestinal symptoms (abdominal cramps, nausea, vomiting and diarrhea) would be expected. Hypotension with dizziness or fainting might also occur. Overdosage symptoms should be treated symptomatically and should be of short duration. Starting with single bolus i.v. injection comparable to the human dose of 0.4 mg/kg, sincalide caused hypotension and bradycardia in dogs. Higher doses injected once or repeatedly in dogs caused syncope and ECG changes in addition. These effects were attributed to sincalide-induced vagal stimulation in that all were prevented by pretreatment with atropine or bilateral vagotomy.

ContrainDications

The preparation is contraindicated in patients hypersensitive to sincalide and in patients with intestinal obstruction.

This monograph has been modified to include the generic and brand name in many instances.

Clinical Pharamacology

When injected intravenously, sincalide produces a substantial reduction in gallbladder size by causing this organ to contract. The evacuation of bile that results is similar to that which occurs physiologically in response to endogenous cholecystokinin. The intravenous (bolus) administration of sincalide causes a prompt contraction of the gallbladder that becomes maximal in 5 to 15 minutes, as compared with the stimulus of a fatty meal which causes a progressive contraction that becomes maximal after approximately 40 minutes. Generally, a: 40 percent reduction in radiographic area of the gallbladder is considered satisfactory contraction, although some patients will show area reduction of 60 to 70 percent.

Like cholecystokinin, sincalide stimulates pancreatic secretion; concurrent administration with secretin increases both the volume of pancreatic secretion and the output of bicarbonate and protein (enzymes) by the gland. This combined effect of secretin and sincalide permits the assessment of specific pancreatic function through measurement and analysis of the duodenal aspirate. The parameters usually determined are: volume of the secretion; bicarbonate concentration; and amylase content (which parallels the content of trypsin and total protein).

Both cholecystokinin and sincalide stimulate intestinal motility, and may cause pyloric contraction which retards gastric emptying.

This monograph has been modified to include the generic and brand name in many instances.

Patient Information

No information provided. Please refer to the WARNINGS and PRECAUTIONS sections.

This monograph has been modified to include the generic and brand name in many instances.

Consumer Overview Uses

No Information Available!

Consumer Overview Side Effect

No Information Available!

Consumer Overview Missed Dose

No Information Available!

Patient Detailed Side Effect

Brand Names: Kinevac

Generic Name: sincalide (Pronunciation: SIN ka lide)

  • What is sincalide (Kinevac)?
  • What are the possible side effects of sincalide (Kinevac)?
  • What is the most important information I should know about sincalide (Kinevac)?
  • What should I discuss with my health care provider before receiving sincalide (Kinevac)?
  • How is sincalide given (Kinevac)?
  • What happens if I miss a dose (Kinevac)?
  • What happens if I overdose (Kinevac)?
  • What should I avoid before or after receiving sincalide (Kinevac)?
  • What other drugs will affect sincalide (Kinevac)?
  • Where can I get more information?

What is sincalide (Kinevac)?

Sincalide is a diagnostic agent that works by stimulating processes in specific organs of the body. Sincalide is injected in preparation for certain medical tests.

Sincalide is used to help diagnose disorders of the gallbladder or pancreas. It is also used to speed up digestion of barium, a contrast agent, given in preparation for x-ray examination of the intestines.

Sincalide may also be used for purposes not listed in this medication guide.

What are the possible side effects of sincalide (Kinevac)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Less serious side effects are more likely, such as:

  • stomach pain or discomfort;
  • nausea, vomiting, diarrhea;
  • headache;
  • feeling light-headed or short of breath;
  • sweating, flushing (warmth, redness, or tingly feeling);
  • sneezing; or
  • mild skin rash.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the Kinevac (sincalide) Side Effects Center for a complete guide to possible side effects

Learn More »

What is the most important information I should know about sincalide (Kinevac)?

You should not receive sincalide if you are allergic to it, or if you have a blockage in your intestines.

Before you receive sincalide, tell your doctor if you have gallstones.

Your medical test or x-ray will be performed shortly after sincalide is injected.

Receiving this medication late in pregnancy may result in a miscarriage or premature labor. Before you receive sincalide, tell your doctor if you are pregnant.

Side Effects Centers
  • Kinevac

Patient Detailed How Take

What should I discuss with my health care provider before receiving sincalide (Kinevac)?

You should not receive sincalide if you are allergic to it, or if you have a blockage in your intestines.

Before you receive sincalide, tell your doctor if you have gallstones.

FDA pregnancy category B. Sincalide is not expected to harm an unborn baby during early pregnancy. However, receiving this medication late in pregnancy may result in a miscarriage or premature labor. Before you receive sincalide, tell your doctor if you are pregnant.

It is not known whether sincalide passes into breast milk or if it could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.

How is sincalide given (Kinevac)?

Sincalide is injected into a vein through an IV. You will receive this injection in a clinic or hospital setting.

Your medical test or x-ray will be performed shortly after sincalide is injected.

Side Effects Centers
  • Kinevac

Patient Detailed Avoid Taking

What happens if I miss a dose (Kinevac)?

Since sincalide is given by a healthcare professional as part of a medical test, you are not likely to miss a dose.

What happens if I overdose (Kinevac)?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

Overdose symptoms may include nausea, vomiting, diarrhea, and stomach cramps.

What should I avoid before or after receiving sincalide (Kinevac)?

Follow your doctor's instructions about any restrictions on food, beverages, or activity.

What other drugs will affect sincalide (Kinevac)?

There may be other drugs that can interact with sincalide. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.

Where can I get more information?

Your doctor or pharmacist can provide more information about sincalide.


Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.

Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 1996-2013 Cerner Multum, Inc. Version: 1.02. Revision date: 12/15/2010.

Your use of the content provided in this service indicates that you have read,understood and agree to the End-User License Agreement,which can be accessed by clicking on this link.

Healthwise

Side Effects Centers
  • Kinevac

Rx Scoops
Featured Topics
Advertisements
Copyrights ©2014: Rx Scoops - Designed & Developed By - GOIGI